BioSpace

TRexBio, Retension raise $161.7M in IPOs; City, Iambic set proposed offering terms

TRexBio and Retension Pharmaceuticals are set to debut Friday, bringing this year’s biotech IPO count to 29 as the sector’s rebound continues. City Therapeutics and Iambic Therapeutics hope to push that number even higher.

By BioSpace

1 min read
TRexBio, Retension raise $161.7M in IPOs; City, Iambic set proposed offering terms
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights